TRAW•benzinga•
Expert Systems Announced Milestone in Traws Pharma's H5N1 Program; Tivoxavir Marboxil Shows Broad-Spectrum Efficacy In Phase 1 Trial With No Adverse Events; Single Dose Maintains Plasma Levels Above EC90 For Over 23 Days
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga